Startups
2017
NANOLIGENT SL
Dirección
Avinguda de Can Domènech, 08193 Cerdanyola del Vallès, España
Datos financieros
Propiedad de CERCA
Barcelona, Spain
1992
Institut de Recerca Sant Pau
Otros accionistas públicos catalanes
Logo
Estado
Estado de la empresaEstado actual de la empresa
Área DeepTech
Descripción
Descripción
Nanoligent es una empresa biotecnológica, spin-off de la Universitat Autònoma de Barcelona (UAB) y del Institut de Recerca de l'Hospital de la Santa Creu I Sant Pau. Nos dedicamos al diseño y desarrollo de fármacos biológicos terapéuticos dirigidos.
Descripción del producto
Our technology allows the design of new protein conjugates organized as nanoparticles and capable of targeting specific biological systems. This protein architecture is highly stable upon administration in vivo, allowing not only long-lasting systemic circulation but also site-specific drug delivery. Precision medicine aiming high therapeutic index and low side effects for oncology.
Nano-sized: Our proteins have the capacity to self-assamble and form nanoparticles that avoid kidney clearance.
Targeted: By means of a specific ligand, Nanoligent’s medicine is able to selectively target cells, delivering the desired cargo
Humanized scaffolds: We have developed humanized scaffolds for our medicine to avoid undesired immune responses.
Protein-only: Our technology involves protein-only nanoparticles that can be degraded naturally in the body.
Cell-killing: Drug conjugation allow our nanoparticles to kill cells while retaining the selectivity. Thus, there is a reduction in systemic toxicity.
Nano-sized: Our proteins have the capacity to self-assamble and form nanoparticles that avoid kidney clearance.
Targeted: By means of a specific ligand, Nanoligent’s medicine is able to selectively target cells, delivering the desired cargo
Humanized scaffolds: We have developed humanized scaffolds for our medicine to avoid undesired immune responses.
Protein-only: Our technology involves protein-only nanoparticles that can be degraded naturally in the body.
Cell-killing: Drug conjugation allow our nanoparticles to kill cells while retaining the selectivity. Thus, there is a reduction in systemic toxicity.